Upregulation of ASPP2 expression alleviates the development of proliferative vitreoretinopathy in a rat model

Yan-Kun Yue, Xiao-Li Chen, Shan Liu, Wu Liu

1Department of Ophthalmology, Fuxing Hospital, Capital Medical University, Beijing 100038, China
2Department of Ophthalmology, Beijing TongRen Hospital, Capital Medical University, Beijing 100730, China

Co-first authors: Yan-Kun Yue and Xiao-Li Chen

Correspondence to: Wu Liu. Department of Ophthalmology, Beijing TongRen Hospital, Capital Medical University, Chongwenmen District, Beijing 100730, China. fuxingyk@sina.com

Received: 2020-12-08  Accepted: 2021-08-09

Abstract

- **AIM:** To investigate whether upregulation of apoptosis-stimulating p53 protein 2 (ASPP2) expression could alleviate the development of proliferative vitreoretinopathy (PVR) in a rat model.
- **METHODS:** ASPP2-lentivirus or scrambled-lentivirus were transfected into ARPE-19 cells, followed with measurements of cell cytotoxicity by cell counting kit-8 assay. ASPP2 upregulation was confirmed by Western blotting and immunocytochemistry. Then ARPE-19 cells pretreated with ASPP2-lentivirus were intravitreally injected to Brown Norway rats to induce PVR models. PVR development and retinal function were evaluated by retinal photography and electroretinography, respectively. Finally, epithelial–mesenchymal transition as well as autophagy were investigated in rats' retinas via Western blotting.
- **RESULTS:** Protein expression of ASPP2 was significantly upregulated by ASPP2-lentivirus transfection in ARPE-19 cells. The development and progression of PVR were impeded significantly in rats with intravitreal injection of ARPE-19 cells pretreated with ASPP2-lentivirus. Accordingly, retinal functions were less affected and PVR grades were much lower in rats with ASPP2-lentivirus compared to scrambled-lentivirus treatment. Moreover, epithelial–mesenchymal transition and autophagy markers were decreased in the retinas of rats treated with ASPP2-lentivirus.
- **CONCLUSION:** ASPP2-lentivirus transfected to ARPE-19 cells mitigates the progression of PVR in rat models, which might be partly through reduced autophagy and attenuated epithelial–mesenchymal transition. ASPP2 might stand as a new approach for PVR treatment in the future.

- **KEYWORDS:** proliferative vitreoretinopathy; apoptosis-stimulating p53 protein 2; epithelial–mesenchymal transition; autophagy; ARPE-19

DOI:10.18240/ijo.2021.12.02


INTRODUCTION

Proliferative vitreoretinopathy (PVR) is a severe eye disease, which usually causes failure and vision losses after surgeries for retinal detachment [1]. PVR can be characterized by the formation of fibrotic epiretinal membranes, and sometimes subretinal and intraretinal membranes. Despite remarkable advances in surgical technique, vision outcome for PVR is still unsatisfactory. Moreover, there is no effective pharmacologic agents for PVR treatment partly due to its unclear and complicated pathogeneses [2-3]. PVR can be caused by many factors and retinal pigment epithelial (RPE) cells are considered as a crucial one. Although no consensus is achieved, a major component of PVR pathophysiology could be roughly depicted [4-5]. First, a retinal tear happens and RPE cells migrate into the vitreous cavity. Subsequently, the RPE cells transit to myofibroblasts/fibrotic cells via epithelial-mesenchymal transition (EMT). Lastly, those fibrotic cells in epiretinal membranes could provide contractile properties, leading to retinal detachment and vision loss. Nevertheless, one big obstacle for PVR research is the lack of widely-accepted animal models which can fully mimic human PVR.

Till now, there is no ideal animal model for PVR studies. Experimental animal models including rabbits, rats and mice have applied either the injection of different cell types or retinal trauma to promote PVR membranes formation or tractional retinal detachment [4-6]. Commonly, PVR membranes
can successfully exist within 1-4 wk after intravitreal injection. We also established a rat model of PVR by vitreous injection of ARPE-19 cells pretreated with apoptosis-stimulating p53 protein 2 (ASPP2)-siRNA, which promoted experimental PVR progression [7]. ASPP2 is a famous member of the evolutionarily conserved ASPP family, which has characteristic sequences of ankyrin repeats, an SH3 domain, and a proline-rich region [10]. ASPP2 has been regarded as a pluripotent molecule including activator for p53 [11-12], binding partner for PAR3 [13], tumor suppressor and EMT regulator [14]. Numerous studies have confirmed that ASPP2 is critical to cell life probably via apoptosis, autophagy and EMT [11-12]. Besides, low expression level of ASPP2 is associated with various cancers, such as pancreatic cancer and hepatocellular carcinoma, indicating a poor clinical outcome [11-14]. Our previous study also suggested that PVR membranes of human specimens had decreased expression of ASPP2 and ASPP2 knockdown promoted PVR formation in vivo partly via the EMT regulation [7]. However, the effects of ASPP2 upregulation during PVR development have not been investigated.

In this study, we tried to explore the function of ASPP2 upregulation on the progression of experimental PVR in a rat model. Specifically, ARPE-19 cells pretreated with ASPP2-lentivirus were injected into the vitreous cavities of Brown Norway (BN) rats to investigate its role in the PVR pathogenesis. Understanding the pathophysiological role of ASPP2 in PVR disease may potentially provide new therapy targets.

### MATERIALS AND METHODS

#### Ethical Approval
All experiments were adhered to the Association for Research in Vision and Ophthalmology (ARVO) statements for the Use of Animals in Ophthalmology and Vision Research. The animal studies were approved by the Animal Care Use Committee of TongRen and FuXing Hospital.

#### Cell Culture and Treatment
Dulbecco’s modified Eagle’s medium (DMEM)/F12 medium (HyClone; Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) were used for ARPE-19 cells (CRL-2302; American Type Culture Collection) culture. The ASPP2-lentivirus-glial fibrillary acidic protein (GFAP) and scrambled-lentivirus-GFAP were synthesized and provided by Shanghai GeneChem Company (Shanghai, China). ASPP2-lentivirus or scrambled-lentivirus were transfected into ARPE-19 cells according to the manufacturer’s instructions. In brief, cells were seeded at the recommended density for 12 h and lentivirus suspension were added accordingly. At 72 h after the transfection, protein was extracted from the cells and Western blot was employed. Stable cell lines were obtained after selection with 6 μg/mL of puromycin for 10 d as previously described [15].

#### Cell Counting Kit-8 Assay
ARPE-19 cells with lentivirus treatment for 48 h and corresponding stable cell lines were plated on a 96-well plate with 100 μL liquid of DMEM/F12. Cell counting kit-8 assay (CCK-8; Beyotime, Jiangsu, China) was used to determine the cell viability at 12, 24, 48, 72, and 96 h after transfection. Cells were starved for 24 h and each well was given 10 μL CCK-8 reagents subsequently. After that, cells were incubated for 1.5 h at 37°C under a humidified atmosphere with 5% CO2. Finally, a test wavelength of 450 nm was chosen to read the absorbance of cells.

#### Western Blotting
After 72 h of lentivirus transfection, overexpression of ASPP2 in the cultured cells was confirmed by Western blotting. Protein of cultured cells were extracted with lysis buffer and frozen at -80°C until use. Protein concentrations of the samples were measured by bicinchoninic acid (BCA) protein assay kit (Pierce, USA) following the manufacturer’s instructions. We loaded 30 μg total proteins in each lane on the 12% sodium dodecyl sulfate polyacrylamide gel. Then we incubated membranes with primary antibody and with secondary antibody and visualized with enhanced chemiluminescence detection reagents (Pierce). The primary antibody was polyclonal antibody against ASPP2 (sc-53861; Santa Cruz). On the day 28 after the intravitreal injection for PVR induction, rats were sacrificed and retinas were gained from the eyeball carefully. Then retinas were given lysis buffer and protein concentration was measured by BCA assay. A total of 50 μg proteins were loaded and incubated with primary antibodies of alpha-SMA (ab32575; Abcam) and LC3-II/I (CST#4108; Cell Signaling Technology). Immunoblot analyses were performed by Quantity One software.

#### Immunocytochemistry
ARPE-19 cells were grown on glass coverslips. After culture for 48 h, we washed coverslips in phosphate buffer saline (PBS), fixed cells in 4% PFA for 15 min and in 10% goat serum for 30 min. Then ASPP2 antibody was incubated overnight at 4°C, followed with incubation of secondary fluorescent antibody for 1 h at 37°C in avoidance of light. After that, DAPI (4, 6-diamino-2-phenylindole) was used for cell nuclei counterstain. Images were visualized using the fluorescence microscope (Leica). Experiments were repeated three times.

#### Intravitreal Injection and PVR Induction
All rat surgeries were under sodium pentobarbital anesthesia. We made best efforts to minimize the rats’ sufferings. PVR experimental models of rats were established as previously described [7]. In brief, a total of 40 specific pathogen-free BN rats (200±10 g, 6-7 wk, male) were used. They were assigned to two groups according to intravitreal injection of ARPE-19 cells pretreated with ASPP2-lentivirus or scrambled-lentivirus. Rats were given anesthesia and pupil dilation. Injection of 1×10^6 stable cell lines of ARPE-19 cells with lentivirus transfection (5 μL) into
the vitreous cavity of BN rats was through a Hamilton syringe fitted with a 32-gauge microneedle. On 1, 3, 7, 14, 21, and 28d after the injection, two masked ophthalmologists examined all rat eyes. Phoenix Micron IV Retinal Imaging Microscope were used for fundus documentary of each rat. PVR was classified according to the criteria suggested by Behar-Cohen et al.[16].

Electroretinography Electroretinography (ERG) was carried out before intravitreal injection, and 7/14d after the injection of ARPE-19 cells for the evaluation of retinal function. The rats were given 8-hour dark adaption, and then anaesthetized with sodium pentobarbital. After that, rat eyes were given 1% tropicamide for pupillary dilatation and 1% proparacaine for topical anaesthetization, followed by one drop of methylcellulose applied for electrodes settings. Briefly, we placed the corneal jet electrodes on the cornea and the reference electrode subcutaneously between the base of the ear and lateral canthus. Then we put the ground electrode on the occiput subcutaneously with dim red light. According to the ISCEV guidelines, we conducted and analyzed ERG recordings.

Statistical Analysis Statistical analysis was conducted with Graph Pad Prism 8 (GraphPad Software, Inc., US). Data were described as mean±SD. CCK-8 results were analyzed by one-way analysis of variance (ANOVA) method and PVR grades were compared by non-parametric Mann-Whitney U test. ERG and Western blot data were analyzed using t-test. A P<0.05 was regarded as statistically significant.

RESULTS

Confirmation of ASPP2 Upregulation in ARPE-19 Cells ASPP2-lentivirus were transfected to ARPE-19 cells successfully, and protein expression level of ASPP2 showed a significant increase compared to the scrambled-lentivirus controls (Figure 1). Upregulation of ASPP2 expression was further confirmed by immunocytochemistry assay (Figure 2).

Effect of ASPP2 Upregulation on the Viability of ARPE-19 Cells Since ASPP2-lentivirus transfection significantly increased the protein expression level of ASPP2, we further investigate its effect on cell viability of ARPE-19. In the CCK-8 assay, cell viability decreased in ASPP2-lentivirus group at 12h but increased at 24h after transfection (P<0.01 and P<0.05, respectively), compared with scrambled-lentivirus group. However, there was no significant differences between ASPP2-lentivirus and scrambled-lentivirus groups at 48, 72, and 96h. Therefore, we chose 48h after the transfection as a timepoint for the studies afterwards. As we used stable cell lines with ASPP2-lentivirus and scrambled-lentivirus transfection for the in vivo experiment, we also measured the viability of those stable cell lines and ARPE-19 cells with 48h lentivirus transfection (Figure 3).

Upregulation of ASPP2 Impeded Induction of Experimental PVR in Rats As shown in Table 1, the severity and rate of PVR had a significant decrease in rats with vitreous injection of ARPE-19 cells pretreated with ASPP2-lentivirus compared to those pretreated with scramble-lentivirus. The grading scheme of PVR severity was similar to the previous studies.[7,16] We used fundus imaging to detect the changes of retinal morphology and PVR formation (Figure 4). Three rats were excluded because of cataract and vitreous hemorrhage after the injection. Therefore, in total 18 rats in ASPP2-lentivirus group and 19 rats in scrambled-lentivirus group.
On day 7 after intravitreal injection, we observed vitreous haze and strands (stage 1) in 2 rats (10.53%) in the scrambled-lentivirus group while none in the ASPP2-lentivirus group. On day 14, six rats (31.58%) in the scrambled-lentivirus group progressed to stage 1 and three rats (15.79%) to stage 2, but only 3 rats (16.67%) in the ASPP2-lentivirus group entered stage 1. The difference between the two groups was statistically significant ($P<0.05$). Similar changes in severity of PVR were observed on day 21 and day 28 respectively ($P<0.05$).

**Effect of ASPP2 Upregulation on Retinal Function in PVR Models** To evaluate the effect of ASPP2 upregulation on the retinal function, ERG data were collected on day 7 and day 14 after the intravitreal injection. Results showed that vitreous injection of ARPE-19 cells caused retinal function changes at early time (day 7) even though the fundus photographs were normal at that time. However, the difference was not
significant between ASPP2-lentivirus and scrambled-lentivirus group (data not shown). At day 14, the difference is statistically significant as shown in Figure 5 and Table 2. The amplitudes of a wave and b waves in scotopic and photopic tests with different stimulus were significantly decreased in rats with scrambled-lentivirus treatment in comparison to ASPP2-lentivirus treatment (\( P < 0.05 \), respectively).

**ASPP2 Upregulation Attenuated Changes of Epithelial-mesenchymal Transition and Autophagy** Since PVR grades were less pronounced in rats with vitreous injection of ARPE-19 cells pretreated with ASPP2-lentivirus compared to those pretreated with scrambled-lentivirus, we next studied the EMT changes in rats’ retinas. As shown in Figure 6, protein expression of alpha-smooth muscle actin (alpha-SMA, an EMT marker) was down-regulated in the ASPP2-lentivirus group. Meanwhile, LC3-II/I, a well-known indicator of autophagy, displayed a decreased expression in the ASPP2-lentivirus group versus the scrambled-lentivirus group.

**DISCUSSION**
In the present research, we studied the effect of vitreous injection of ARPE-19 cells pretreated with ASPP2-lentivirus on the development of experimental PVR in BN rats. Our study indicated that ASPP2 upregulation significantly decreased the rate of PVR induction and degraded PVR severities in vivo. Many other studies suggested that the retinal function was damaged in PVR development\(^{[4,17-18]}\). In accordance with that, we also found that retinal function decreased during PVR progression in the control group, but ASPP2 upregulation alleviated the damage significantly. Moreover, although ASPP2 is reported to be related to cell viability\(^{[19]}\), our study showed that ASPP2 upregulation did not affect the cell viability of APRE-19 at 48, 72, and 96h after transfection. What worth notify is that cell viability decreased at 12h but increased at 24h after transfection with ASPP2-lentivirus, which might reflect the cell adaption to lentivirus transfection. Specifically, ASPP2 upregulation may promote cell apoptosis in ARPE-19 cells but this effect was weakened by cell self-regulation. However, the exact pathway is unclear and need further study. As far as we concerned, the present study reported the effect of ASPP2 upregulation on PVR progression in a rat model for...
the first time. But our study has some limitations. First, we used ARPE-19 cells for vitreous injection which may cause some degree of inflammation, but there are other studies which also chose ARPE-19 cells injection for experimental PVR\cite{4,20}. The reason we chose ARPE-19 is that it is stable in different passages and may result in minimal variations. Another limitation is lack of research on the molecular mechanism of ASPP2 upregulation \textit{in vitro}. As we previously reported, ASPP2 knockdown promoted PVR development possibly through the EMT changes of ARPE-19 cells\cite{7}. However, in this study we did not find any obvious changes of EMT phenotype in ARPE-19 cells with ASPP2-lentivirus treatment (data not shown). Unlike ASPP2 knockdown, which may be a trigger for EMT, we suppose that ASPP2 upregulation alone may not cause EMT changes in ARPE-19 cells.

Then, how can ASPP2 upregulation negatively affect PVR progression in rats? It might be rational to speculate that ASPP2 related autophagy may participate in this process. Autophagy is known as a lysosomal-dependent cellular degradation process, during which the cell digests its own proteins and organelles\cite{13}. Autophagy plays an important role in the pathogenesis of diverse diseases, including neuronal degeneration, aging and cancer. Inhibition of autophagy resulted in developmental delay via EMT reduction in the gastrulation of chick embryos\cite{21}. Similarly, inhibition of autophagy significantly weakened the TGF-β2 mediated EMT in RPE cells, as reported by Miao \textit{et al}\cite{22}. Our results are consistent to those findings, as decreased expressions of autophagy and EMT markers are found in the retinas of rats treated with ASPP2-lentivirus compared to those with scrambled-lentivirus. Meanwhile, there is increasing evidence demonstrating that ASPP2 is critical to autophagy. ASPP2 upregulation negatively regulates autophagic flux in pancreatic cancer\cite{14}, whereas downregulation of ASPP2 facilitates autophagic activity in hepatocellular carcinoma cells\cite{13}. In addition, our \textit{in vivo} results also suggest that ASPP2 upregulation might lead to reduced autophagy and attenuated EMT changes. However, there is a complex interaction between ASPP2, autophagy and EMT, which needs in-depth investigation.

In conclusion, our study indicated that ASPP2 upregulation impeded the development of experimental PVR and mitigated PVR severities in BN rats. ASPP2 might be a novel target for the prevention and treatment of PVR disease.
ACKNOWLEDGEMENTS

We want to thank Beijing Ophthalmology & Visual Sciences Key Laboratory for their support.

Foundation: Supported by National Natural Science Foundation of China (No.81800827).

Conflicts of Interest: Yue YK, None; Chen XL, None; Liu S, None; Liu W, None.

REFERENCES